I keep from going numb by remembering the odds for
Post# of 30027
(Total Views: 548)
Posted On: 11/08/2018 9:44:43 AM
Re: investorxc #27297
I keep from going numb by remembering the odds for any biotech to survive and take off are slim, very slim. That's why the risk to reward ratio.
I also remind myself often what Dr. Rubinfeld said.
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
He said this 6 years ago on November 06, 2012. Now I've read a ton of positive research on MANF in not only Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury he mentioned, but many more. I don't have time to post like I used to, but that doesn't mean there isn't a lot o information out there every week.
So many indications. So many institutions doing research to find even more. Very little of this research the company had to fund.
Every time the sp goes down people get bummed. When it goes up, people get hopeful. The people that play the games on the OTC know exactly that and play on peoples emotions.
Since I am not buying or selling I could careless if the sp is .02. or .05. It' still down a tremendous amount either way. When it starts swing a buck in either direction, I'll start to celebrate or worry depending on which direction.
I also remind myself often what Dr. Rubinfeld said.
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
He said this 6 years ago on November 06, 2012. Now I've read a ton of positive research on MANF in not only Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury he mentioned, but many more. I don't have time to post like I used to, but that doesn't mean there isn't a lot o information out there every week.
So many indications. So many institutions doing research to find even more. Very little of this research the company had to fund.
Every time the sp goes down people get bummed. When it goes up, people get hopeful. The people that play the games on the OTC know exactly that and play on peoples emotions.
Since I am not buying or selling I could careless if the sp is .02. or .05. It' still down a tremendous amount either way. When it starts swing a buck in either direction, I'll start to celebrate or worry depending on which direction.
(7)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼